Collectively, the current evidence-based studies of PD-1 blockade monotherapy in patients with advanced NSCLC was mainly focused on relatively young patients, suggesting that the efficacy and safety of PD-1 inhibitors in elderly NSCLC patients over 65 years was still scanty. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.